CCL11



CCL11

G1GG1P2PP2A3AA3S4SS4V5VV5P6PP6T7TT7T8TT8C9CC9C10CC10F11FF11N12NN12L13LL13A14AA14N15NN15R16RR16K17KK17I18II18P19PP19L20LL20Q21QQ21R22RR22L23LL23E24EE24S25SS25Y26YY26R27RR27R28RR28I29II29T30TT30S31SS31G32GG32K33KK33C34CC34P35PP35Q36QQ36K37KK37A38AA38V39VV39I40II40F41FF41K42KK42T43TT43K44KK44L45LL45A46AA46K47KK47... and 27 more residue(s)...... and 27 more residue(s)

SMILES None
InChIKey None
Sequence GPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Ligand site mutations CCR3

Bioactivities

CCL11

G1GG1P2PP2A3AA3S4SS4V5VV5P6PP6T7TT7T8TT8C9CC9C10CC10F11FF11N12NN12L13LL13A14AA14N15NN15R16RR16K17KK17I18II18P19PP19L20LL20Q21QQ21R22RR22L23LL23E24EE24S25SS25Y26YY26R27RR27R28RR28I29II29T30TT30S31SS31G32GG32K33KK33C34CC34P35PP35Q36QQ36K37KK37A38AA38V39VV39I40II40F41FF41K42KK42T43TT43K44KK44L45LL45A46AA46K47KK47... and 27 more residue(s)...... and 27 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Ligand site mutations CCR3

Compound is not listed as a drug.